156 related articles for article (PubMed ID: 19844746)
1. Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients.
Grenda R
Pediatr Nephrol; 2010 Apr; 25(4):747-52. PubMed ID: 19844746
[TBL] [Abstract][Full Text] [Related]
2. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
[TBL] [Abstract][Full Text] [Related]
3. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
[TBL] [Abstract][Full Text] [Related]
5. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
[TBL] [Abstract][Full Text] [Related]
6. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
[TBL] [Abstract][Full Text] [Related]
7. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
8. Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation.
Höcker B; Weber LT; Feneberg R; Drube J; John U; Fehrenbach H; Pohl M; Zimmering M; Fründ S; Klaus G; Wühl E; Tönshoff B
Nephrol Dial Transplant; 2010 Feb; 25(2):617-24. PubMed ID: 19793929
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
10. Steroid avoidance or withdrawal for kidney transplant recipients.
Pascual J; Zamora J; Galeano C; Royuela A; Quereda C
Cochrane Database Syst Rev; 2009 Jan; (1):CD005632. PubMed ID: 19160257
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid avoidance in pediatric renal transplantation: can it be achieved?
Vidhun JR; Sarwal MM
Paediatr Drugs; 2004; 6(5):273-87. PubMed ID: 15449967
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
13. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids use in kidney transplant setting.
De Lucena DD; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1023-1041. PubMed ID: 30265586
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
[TBL] [Abstract][Full Text] [Related]
17. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
18. Risk of steroid withdrawal in pediatric renal transplant patients with suspected steroid toxicity.
Klaus G; Jeck N; Konrad M; Förster B; Soergel M
Clin Nephrol; 2001 Dec; 56(6):S37-42. PubMed ID: 11770812
[TBL] [Abstract][Full Text] [Related]
19. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
